Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568749 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2024013955 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Blood
August 2024
Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
Article Synopsis
- Patients with mantle cell lymphoma (MCL) who relapse are split into two groups: early and late progression, based on how long it's been since their diagnosis.
- This study looked at treatment outcomes for 385 late-POD patients treated with two kinds of therapies: Bruton tyrosine kinase inhibitors (BTKi) and chemoimmunotherapy (CIT).
- Findings showed that BTKi treatment led to longer survival without disease progression compared to CIT, suggesting it might be the better choice for these patients.
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
Blood Adv
January 2024
Department of Immunology, Genetics and Pathology, Unit of Cancer Precision Medicine, Uppsala University, Uppsala, Sweden.
Despite improvements in treatment of mantle cell lymphoma (MCL), most patients eventually relapse. In this multicenter phase 1b/2 trial, we evaluated safety and efficacy of minimal residual disease (MRD)-driven venetoclax, lenalidomide, and rituximab (venetoclax-R2) in relapsed/refractory (R/R) MCL and explored the feasibility of stopping treatment in molecular remission. The primary end point was overall response rate (ORR) at 6 months.
View Article and Find Full Text PDFMYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and /p53 - a Nordic Lymphoma Group study.
Haematologica
April 2024
Department of Immunotechnology, Lund University.
The transcription factor MYC is a well-described oncogene with an important role in lymphomagenesis, but its significance for clinical outcome in mantle cell lymphoma (MCL) remains to be determined. We performed an investigation of the expression of MYC protein in a cohort of 251 MCL patients complemented by analyses of structural aberrations and mRNA, in a sub-cohort of patients. Fourteen percent (n=35) of patients showed high MYC protein expression with >20% positive cells (MYChigh), among whom only one translocation was identified, and 86% (n=216) of patients showed low MYC protein expression.
View Article and Find Full Text PDFSoluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma.
Blood Adv
September 2023
Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden.
The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed toward the tumor immune microenvironment, where macrophages play an important role. In MCL, the presence of M2 macrophages defined by CD163 expression in diagnostic biopsies has been associated with a worse prognosis. An alternative way to assess the abundance of M2 macrophages is by measuring the level of soluble CD163 in serum (sCD163).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!